Psychedelics in the treatment of unipolar mood disorders : a systematic review James J.H. Rucker, Luke A. Jelen, Sarah Flynn, Kyle D. Frowde and Allan H. Young Journal of Psychopharmacology, 2016, 1-10 DOI: 10.1177/0269881116679368 Abstract Unipolar mood disorders, including major depressive disorder and persistent depressive disorder (dysthymia), confer high rates of disability and mortality and a very high socioeconomic burden. Current treatment is suboptimal in most cases and there is little of note in the pharmaceutical development pipeline. The psychedelic drugs, including lysergic acid diethylamide and psilocybin, were used extensively in the treatment of mood disorders, and other psychiatric conditions, before their prohibition in the [...]
Lire la suiteEfficacy and Safety of Intranasal Esketamine for the Rapid Reduction of Symptoms of Depression and Suicidality in Patients at Imminent Risk for Suicide: Results of a Double-Blind, Randomized, Placebo-Controlled Study Carla M. Canuso, M.D., Jaskaran B. Singh, M.D., Maggie Fedgchin, Pharm.D., Larry Alphs, M.D., Ph.D., Rosanne Lane, M.A.S., Pilar Lim, Ph.D., Christine Pinter, M.S., David Hough, M.D., Gerard Sanacora, M.D., Ph.D., Husseini Manji, M.D., Wayne C. Drevets, M.D. American Journal of Psychiatry, 2018, 175, 620–630 doi: 10.1176/appi.ajp.2018.17060720 Objective : The authors compared the efficacy of standardof- care treatment plus intranasal esketamine or placebo for rapid reduction of symptoms of major depression, including suicidality, among [...]
Lire la suiteThe paradoxical psychological effects of lysergic acid diethylamide (LSD) R. L. Carhart-Harris, M. Kaelen, M. Bolstridge, T. M. Williams, L. T. Williams, R. Underwood, A. Feilding and D. J. Nutt Psychological Medicine, 2016, 46, 1379–1390. doi:10.1017/S0033291715002901 Background : Lysergic acid diethylamide (LSD) is a potent serotonergic hallucinogen or psychedelic that modulates consciousness in a marked and novel way. This study sought to examine the acute and mid-term psychological effects of LSD in a controlled study. Method : A total of 20 healthy volunteers participated in this within-subjects study. Participants received LSD (75 μg, intravenously) on one occasion and placebo (saline, intravenously) on another, in a [...]
Lire la suitePotential Therapeutic Effects of Psilocybin Matthew W. Johnson & Roland R. Griffiths Neurotherapeutics, 2017, 14, 734–740 DOI 10.1007/s13311-017-0542-y Abstract Psilocybin and other 5-hydroxytryptamine2A agonist classic psychedelics have been used for centuries as sacraments within indigenous cultures. In the mid-twentieth century they were a focus within psychiatry as both probes of brain function and experimental therapeutics. By the late 1960s and early 1970s these scientific inquires fell out of favor because classic psychedelics were being used outside of medical research and in association with the emerging counter culture. However, in the twenty-first century, scientific interest in classic psychedelics has returned and grown as a result of [...]
Lire la suiteL’expérimentation du cannabis thérapeutique officiellement autorisée en France Une décision de l’agence française du médicament ouvre la voie à un test en situation réelle réservé aux patients en impasse thérapeutique. Le Monde avec AFP Publié le 11 juillet 2019 à 11h20 - Mis à jour le 11 juillet 2019 à 11h26 Un plant de cannabis thérapeutique, Israël, le 24 janvier 2019. Amir Cohen / REUTERS C’est une nouvelle étape vers l’expérimentation du cannabis thérapeutique en France : l’Agence nationale de sécurité du médicament et des produits de santé (ANSM) a validé jeudi 11 juillet le cadre proposé fin juin par un groupe [...]
Lire la suiteLysergic acid diethylamide : a drug of ‘use’ ? Saibal Das, Preeti Barnwal, Anand Ramasamy, Sumalya Sen and Somnath Mondal Therapeutic Advances in Psychopharmacology, 2016, Vol. 6, (3), 214–228 DOI: 10.1177/2045125316640440 Abstract : Lysergic acid diethylamide (LSD), described as a classical hallucinogen, began its journey from the middle of the last century following an accidental discovery. Since then, it was used as a popular and notorious substance of abuse in various parts of the world. Its beneficial role as an adjunct to psychotherapy was much unknown, until some ‘benevolent’ experiments were carried out over time to explore some of its potential uses. But, many [...]
Lire la suiteCannabidiol Does Not Dampen Responses to Emotional Stimuli in Healthy Adults David L. Arndt and Harriet de Wit Cannabis and Cannabinoid Research, 2017, 2, (1), 105-113 DOI: 10.1089/can.2017.0014 Abstract Introduction : Cannabidiol (CBD) is a nonpsychoactive constituent of whole plant cannabis that has been reported to reduce anxiety-like behaviors in both pre-clinical and human laboratory studies. Yet, no controlled clinical studies have demonstrated its ability to reduce negative mood or dampen responses to negative emotional stimuli in humans. The objective of this study was to investigate the effects of CBD on responses to negative emotional stimuli, as a model for its potential anxiety-reducing effects. Materials and [...]
Lire la suiteThe Neurobiology of Psychedelic Drugs: Implications for the Treatment of Mood Disorders Franz X. VOLLENWEIDER & Michael KOMETER Nature Reviews Neuroscience, 2010, 11, (9), 642-51 DOI: 10.1038/nrn2884 Abstract After a pause of nearly 40 years in research into the effects of psychedelic drugs, recent advances in our understanding of the neurobiology of psychedelics, such as lysergic acid diethylamide (LSD), psilocybin and ketamine have led to renewed interest in the clinical potential of psychedelics in the treatment of various psychiatric disorders. Recent behavioural and neuroimaging data show that psychedelics modulate neural circuits that have been implicated in mood and affective disorders, and can reduce the clinical [...]
Lire la suiteCannabis à visée thérapeutique en France : l’ANSM souscrit au cadre de la phase expérimentale de mise à disposition proposé par le Comité d’experts - Point d'information 11/07/2019 L’Agence nationale de sécurité du médicament et des produits de santé (ANSM) souscrit aux propositions du groupe d’experts (CSST) publiées le 28 juin sur le cadre pratique de l’accès au cannabis à visée thérapeutique en vue d’une expérimentation en France. L’agence et le ministère des solidarités et de la santé engagent dès à présent les travaux nécessaires à la mise en place de l’expérimentation.Le comité d’experts mis en place par l’ANSM en septembre 2018 [...]
Lire la suiteCannabinoids in Parkinson's Disease Mario Stampanoni Bassi, Andrea Sancesario, Roberta Morace, Diego Centonze, and Ennio Iezzi Cannabis and Cannabinoid Research, 2017, Volume 2.1 DOI: 10.1089/can.2017.0002 Abstract The endocannabinoid system plays a regulatory role in a number of physiological processes and has been found altered in different pathological conditions, including movement disorders. The interactions between cannabinoids and dopamine in the basal ganglia are remarkably complex and involve both the modulation of other neurotransmitters (c-aminobutyric acid, glutamate, opioids, peptides) and the activation of different receptors subtypes (cannabinoid receptor type 1 and 2). In the last years, experimental studies contributed to enrich this scenario reporting interactions between cannabinoids [...]
Lire la suite